163 related articles for article (PubMed ID: 8803661)
1. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
[TBL] [Abstract][Full Text] [Related]
3. Subjective response to neuroleptics and the quality of life: implications for treatment outcome.
Awad AG; Hogan TP
Acta Psychiatr Scand Suppl; 1994; 380():27-32. PubMed ID: 7914044
[TBL] [Abstract][Full Text] [Related]
4. Subjective response to neuroleptics in schizophrenia.
Awad AG
Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in schizophrenia: insight and subjective response to neuroleptics.
Browne S; Garavan J; Gervin M; Roe M; Larkin C; O'Callaghan E
J Nerv Ment Dis; 1998 Feb; 186(2):74-8. PubMed ID: 9484306
[TBL] [Abstract][Full Text] [Related]
6. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
de Millas W; Lambert M; Naber D
Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
[TBL] [Abstract][Full Text] [Related]
7. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review.
Vothknecht S; Schoevers RA; de Haan L
Aust N Z J Psychiatry; 2011 Mar; 45(3):182-92. PubMed ID: 21438745
[TBL] [Abstract][Full Text] [Related]
8. Rating of medication influences (ROMI) scale in schizophrenia.
Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A
Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162
[TBL] [Abstract][Full Text] [Related]
9. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
Lambert M; Schimmelmann BG; Karow A; Naber D
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
[TBL] [Abstract][Full Text] [Related]
10. [Viewpoint of schizophrenic patients: a European survey].
Courtet P
Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
[TBL] [Abstract][Full Text] [Related]
11. Drugs and the quality of life: the patient's point of view.
Diamond R
J Clin Psychiatry; 1985 May; 46(5 Pt 2):29-35. PubMed ID: 2859278
[TBL] [Abstract][Full Text] [Related]
12. Subjective neuroleptic response and treatment outcome under open and double-blind conditions--a preliminary report.
Pi E; Sramek J; Johnson T; Herrera J; Heh C; Costa J; Cutler N; Ananth J
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):921-8. PubMed ID: 1980542
[TBL] [Abstract][Full Text] [Related]
13. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
Taira M; Hashimoto T; Takamatsu T; Maeda K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
[TBL] [Abstract][Full Text] [Related]
14. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
15. Early treatment events and prediction of response to neuroleptics in schizophrenia.
Awad AG; Hogan TP
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):585-8. PubMed ID: 2868492
[TBL] [Abstract][Full Text] [Related]
16. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
[TBL] [Abstract][Full Text] [Related]
17. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
18. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
Staring AB; Mulder CL; Duivenvoorden HJ; De Haan L; Van der Gaag M
Schizophr Res; 2009 Aug; 113(1):27-33. PubMed ID: 19525092
[TBL] [Abstract][Full Text] [Related]
19. Subjective well-being and quality of life under atypical antipsychotic treatment.
Karow A; Naber D
Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
[TBL] [Abstract][Full Text] [Related]
20. Subjective utility ratings of neuroleptics in treating schizophrenia.
Finn SE; Bailey JM; Schultz RT; Faber R
Psychol Med; 1990 Nov; 20(4):843-8. PubMed ID: 1980954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
